Sugi Predict

Sugi Predict / Targets / PLAUR

PLAUR

Urokinase plasminogen activator surface receptor · Q03405 · PLAUR on Sugi Atlas →

5,650 patent compounds predicted against PLAUR, 4,049 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3708812 SCHEMBL3708812 0.50 7/20
SCHEMBL5014381 SCHEMBL5014381 0.52 6/20
SCHEMBL6164135 SCHEMBL6164135 0.47 6/20
SCHEMBL3695765 SCHEMBL3695765 0.46 5/20
SCHEMBL2480771 SCHEMBL2480771 0.56 4/20
SCHEMBL2628847 SCHEMBL2628847 0.53 4/20
SCHEMBL2628848 SCHEMBL2628848 0.53 4/20
SCHEMBL6163593 SCHEMBL6163593 0.48 4/20
SCHEMBL6164221 SCHEMBL6164221 0.48 4/20
SCHEMBL938496 SCHEMBL938496 0.48 4/20
SCHEMBL5859251 SCHEMBL5859251 0.43 4/20
SCHEMBL5322283 SCHEMBL5322283 0.55 3/20
SCHEMBL4540201 SCHEMBL4540201 0.51 3/20
SCHEMBL5321539 SCHEMBL5321539 0.51 3/20
SCHEMBL2796439 SCHEMBL2796439 0.49 3/20
SCHEMBL6163447 SCHEMBL6163447 0.49 3/20
SCHEMBL5012763 SCHEMBL5012763 0.48 3/20
SCHEMBL4975367 SCHEMBL4975367 0.48 3/20
SCHEMBL2778040 SCHEMBL2778040 0.43 3/20
SCHEMBL2800853 SCHEMBL2800853 0.43 3/20

Clinical trials — most relevant to PLAUR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section PHASE4COMPLETED
suPAR to Guide Antibiotics in Emergency Department PHASE2/PHASE3UNKNOWN
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) PHASE3RECRUITING
Pharmacoinvasive Therapy With Prourokinase PHASE2/PHASE3COMPLETED
Thrombolysis of Urokinase for Minor Stroke PHASE3COMPLETED
suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE) PHASE2COMPLETED
Ketamine for Thrombolysis in Acute Ischemic Stroke PHASE1/PHASE2UNKNOWN
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia PHASE2COMPLETED
Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke PHASE2COMPLETED
SuPAR in Adult Patients With Covid-19 nanCOMPLETED
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) nanCOMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
Hemospec Device for the Diagnosis of Sepsis nanCOMPLETED
Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage nanCOMPLETED
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence nanWITHDRAWN
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION
Dietary Seaweed and Early Breast Cancer: A Randomized Trial nanCOMPLETED
Biomarkers of AKI in Patients Receiving Daratumumab nanCOMPLETED
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer nanCOMPLETED
Use of suPAR Algorithm for the ED Decision Making nanCOMPLETED
Surgical Revascularisation and Nerve Stimulation Trial nanWITHDRAWN
LRP1 and Colon Cancer nanUNKNOWN
PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors nanUNKNOWN
A Lifestyle Intervention to Improve in Vitro Fertilization Results nanUNKNOWN
Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis nanCOMPLETED
Role of the Endothelium in Stroke-like Episode Among CDG Patients nanCOMPLETED
Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy nanCOMPLETED
Gap Junction Potentiation of Endothelial Function With Rotigaptide nanCOMPLETED
Thrombin Regulated Platelet Activation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PLAUR binder may also engage these)

ProteinNameSimilarity
Q9GK80 — 1.000 Q9GK80 →
Q9GK79 — 1.000 Q9GK79 →
P49616 — 1.000 P49616 →
Q9GK78 — 1.000 Q9GK78 →
Q9GK77 — 0.999 Q9GK77 →
Q05588 — 0.998 Q05588 →
P35456 — 0.991 P35456 →
Q9D7Z7 — 0.988 Q9D7Z7 →
Q6UWN5 — 0.985 Q6UWN5 →
P83106 — 0.985 P83106 →
Q6UX82 — 0.985 Q6UX82 →
H3BJG9 — 0.984 H3BJG9 →
Q91YK8 — 0.984 Q91YK8 →
O95274 — 0.983 O95274 →
Q9JMI7 — 0.981 Q9JMI7 →
A0JNL5 — 0.981 A0JNL5 →
Q924B5 — 0.981 Q924B5 →
P83107 — 0.980 P83107 →
Q8CHN2 — 0.979 Q8CHN2 →
Q9Z0K7 — 0.979 Q9Z0K7 →
Q8K1T5 — 0.979 Q8K1T5 →
O55162 — 0.978 O55162 →
Q14210 — 0.978 Q14210 →
Q148C3 — 0.977 Q148C3 →
Q9BY14 — 0.977 Q9BY14 →
O55006 — 0.977 O55006 →
Q9Z1Q4 — 0.977 Q9Z1Q4 →
P55000 — 0.977 P55000 →
Q9D7S0 — 0.976 Q9D7S0 →
A6NC86 — 0.976 A6NC86 →